The Asia Pacific market for Insulin is expected to reach USD 15.04 billion by 2020, according to a new study by Grand View Research, Inc. Growing regional prevalence of diabetes, increasing market penetration rates of modern insulin products in emerging markets such as India and China is expected to drive market growth during the forecast period. Furthermore, patent expiration of key products such as Lantus is expected to trigger the manufacturing of biosimilars from local manufacturers such as Biocon.
http://www.grandviewresearch.com/industry-analysis/asia-pacific-insulin-market
No comments:
Post a Comment